Impact of High-Dose Rifampicin on Linezolid Pharmacokinetics in Tuberculous Meningitis
Dvijen C. Purohit·Rada M Savic·Paddy Kafeero·Freddie Kibengo·M J Zimmerman·Veronique D'artois·Felicia C. Chow·Rob C. van Wijk
Abstract Background Tuberculous meningitis (TBM), a severe form of extrapulmonary tuberculosis, requires sustained therapeutic drug concentrations in the central nervous system (CNS). Linezolid is a promising treatment for TBM due to excellent CNS penetration and bactericidal activity against Mycobacterium tuberculosis. However, co-administration with rifampicin may alter linezolid pharmacokinetics (PK), potentially reducing efficacy due to drug-drug interactions. Methods We utilized data from t